Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | HINT1 | P49773 | 1/20 | 0.51 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888070 | 1.00 | HPGD (0.57) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL17438077 | 0.96 | HPGD (0.57) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL15832464 | 0.94 | HPGD (0.56) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL30670293 | 0.93 | HPGD (0.55) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL21344309 | 0.93 | NT5E (0.55) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL15328981 | 0.92 | HPGD (0.55) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL15328959 | 0.92 | HPGD (0.56) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL20302626 | 0.92 | HPGD (0.56) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL23343338 | 0.92 | HPGD (0.63) | HPGDNT5ETAS1R3TAS1R1IMPDH2 | |
| SCHEMBL23149828 | 0.91 | NT5E (0.55) | HPGDNT5ETAS1R3TAS1R1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144928-B2 | Double stranded oligonucleotide compounds comprising positional modifications | QUARK PHARMACEUTICALS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-10093923-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2018-10-09 | — | — | US | disclosed |
| US-10059942-B2 | Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues | BIO-LAB LTD. (IL) | 2018-08-28 | — | — | US | disclosed |
| EP-2855679-B1 | THERAPEUTIC OLIGONUCLEOTIDES COMPRISING PYRAZOLOTRIAZINE NUCLEOTIDE ANALOGUES | QBI ENTPR LTD (IL) | 2018-07-18 | — | — | EP | disclosed |
| EP-2521783-B1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS INC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2585594-B1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160355805-A1 | Double Stranded Oligonucleotide Compounds Comprising Positional Modifications | QUARK PHARMACEUTICALS, INC. | 2016-12-08 | — | — | US | disclosed |
| EP-3012324-A2 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Corporation (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-2649181-B1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160108399-A1 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20150166990-A1 | THERAPEUTIC OLIGONUCLEOTIDES COMPRISING PYRAZOLOTRIAZINE NUCLEOTIDE ANALOGUES | BIO-LAB LTD. (IL) | 2015-06-18 | — | — | US | disclosed |
| US-20150159154-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-9045755-B2 | Double stranded RNA compounds to RhoA and use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8859751-B2 | Oligonucleotide compounds comprising non-nucleotide overhangs | QUARK PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140235695-A1 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION | 2014-08-21 | — | — | US | disclosed |
| US-8710209-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2014-04-29 | — | — | US | disclosed |
| US-20130324591-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130137750-A1 | DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF | QUARK PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130035368-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | QUARK PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Technical Corporation | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178157-A1 | MODULATION OF HSP47 EXPRESSION | HSPA1A, HSPH1, HSPA8 | HPGD 3102/4885NT5E 3596/4885TAS1R3 3411/4885 |
| US-20130035368-A1 | OLIGONUCLEOTIDE COMPOUNDS COMPRISING NON-NUCLEOTIDE OVERHANGS | DCLRE1B, SNRPE, UPF1 | HPGD 4084/4885NT5E 183/4885TAS1R3 3038/4885 |
| US-10093923-B2 | Modulation of HSP47 expression | HSPA1A, HSPH1, HSPA8 | HPGD 3102/4885NT5E 3596/4885TAS1R3 3411/4885 |
| US-10059942-B2 | Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues | RNASEH1, RNGTT, EIF2AK2 | HPGD 4104/4885NT5E 222/4885TAS1R3 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.